Provided By GlobeNewswire
Last update: May 14, 2025
SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences:
Read more at globenewswire.comNASDAQ:MYGN (6/12/2025, 2:31:19 PM)
5.12
-0.06 (-1.16%)
Find more stocks in the Stock Screener